Physician profile
James T Corpus
NPI 1801862586
$9,809.36
in general payments reported to CMS, 2019-2025
39 companies · $2,462 in 2025
The $2,462 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,056 · 2020: $1,154 · 2021: $717 · 2022: $890 · 2023: $1,058 · 2024: $1,472 · 2025: $2,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,988 · Education: $3.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,987.56 |
| Education | $3.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,201.68 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $961.50 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $878.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $740.20 | 2019-2025 | |
| Amarin Pharma, INC. | $681.56 | 2019-2023 | |
| Lilly USA, LLC | $625.56 | 2019-2025 | Mounjaro, Zepbound |
| Azurity Pharmaceuticals, INC. | $592.14 | 2023-2025 | Edarbyclor, Edarbyclor, Azmiro |
| Pfizer INC. | $572.71 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $498.11 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $308.41 | 2024-2025 | Purified Cortrophin Gel |
| Allergan, INC. | $298.20 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $279.06 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $239.37 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Vanda Pharmaceuticals INC. | $224.90 | 2025 | Fanapt, Hetlioz |
| Arbor Pharmaceuticals, INC. | $224.34 | 2019-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Corpus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.